Solid oral dosage forms of valsartan
AssigneeNovartis AG
InventorsRobert Frank Wagner, Yoshimitsu Katakuse, Takashi Taike, Fujiki Yamato, Manfred Kohlmeyer
Life of this patent
Estimating the term…
Abstract
The present invention is concerned with solid oral dosage forms of comprising a) an active agent selected from valsartan and optionally HCTZ , and b) Pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.
Claims24
A compressed solid dosage form comprising:
- (a) an active agent comprising an effective amount of valsartan or a pharmaceutically acceptable salt thereof;
- and,
- (b) at least one pharmaceutically acceptable additive;
- wherein the active agent is present in an amount of more than 35% by weight based on the total weight of the compressed solid dosage form and wherein said dosage form exhibits accelerated release of the active agent.
A compressed solid dosage form comprising an active agent comprising an effective amount of valsartan or a pharmaceutically acceptable salt thereof an effective amount of HCTZ;
- and, at least one pharmaceutically acceptable additive wherein the active agent is present in an amount of more than 35% by weight based on the total weight of the compressed solid dosage form and wherein said dosage form exhibits accelerated release of the active agent.
A compressed solid dosage form comprising;
- (a) an active agent comprising an effective amount of valsartan or a pharmaceutically acceptable salt thereof;
- and,
- (b) at least one pharmaceutically acceptable additive;
- wherein the active agent is present in an amount of more than 35% by weight based on the total weight of the compressed solid dosage form, and wherein said damage form exhibits delayed release of the active agent.
A compressed solid dosage form comprising an active agent comprising an effective amount of valsartan or a pharmaceutically acceptable salt thereof;
- an effective amount of HCTZ;
- and, at least one pharmaceutically acceptable additive wherein the active agent is present in an amount of more than 35% by weight based on the total weight of the compressed solid dosage form and wherein said dosage form exhibits delayed release of the active agent.
Dependencies are inferred from the claim text.